Last reviewed · How we verify

FluBlok Influenza Vaccination

Protein Sciences Corporation · Phase 3 active Biologic

FluBlok Influenza Vaccination is a Recombinant protein vaccine Biologic drug developed by Protein Sciences Corporation. It is currently in Phase 3 development for Prevention of influenza illness caused by influenza A and B viruses in adults 18 years of age and older. Also known as: FluBlok, rHA, rHA0, recombinant hemagglutinin.

FluBlok is a recombinant influenza vaccine that stimulates the immune system to produce antibodies against influenza virus surface proteins.

FluBlok is a recombinant influenza vaccine that stimulates the immune system to produce antibodies against influenza virus surface proteins. Used for Prevention of influenza illness caused by influenza A and B viruses in adults 18 years of age and older.

At a glance

Generic nameFluBlok Influenza Vaccination
Also known asFluBlok, rHA, rHA0, recombinant hemagglutinin
SponsorProtein Sciences Corporation
Drug classRecombinant protein vaccine
TargetInfluenza hemagglutinin (HA)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

FluBlok uses recombinant DNA technology to produce hemagglutinin (HA) antigens from influenza virus strains without using eggs or live virus. The recombinant HA proteins are presented to the immune system to generate protective antibody responses against seasonal influenza strains. This approach allows for faster production and avoids potential issues associated with egg-based vaccine manufacturing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about FluBlok Influenza Vaccination

What is FluBlok Influenza Vaccination?

FluBlok Influenza Vaccination is a Recombinant protein vaccine drug developed by Protein Sciences Corporation, indicated for Prevention of influenza illness caused by influenza A and B viruses in adults 18 years of age and older.

How does FluBlok Influenza Vaccination work?

FluBlok is a recombinant influenza vaccine that stimulates the immune system to produce antibodies against influenza virus surface proteins.

What is FluBlok Influenza Vaccination used for?

FluBlok Influenza Vaccination is indicated for Prevention of influenza illness caused by influenza A and B viruses in adults 18 years of age and older.

Who makes FluBlok Influenza Vaccination?

FluBlok Influenza Vaccination is developed by Protein Sciences Corporation (see full Protein Sciences Corporation pipeline at /company/protein-sciences-corporation).

Is FluBlok Influenza Vaccination also known as anything else?

FluBlok Influenza Vaccination is also known as FluBlok, rHA, rHA0, recombinant hemagglutinin.

What drug class is FluBlok Influenza Vaccination in?

FluBlok Influenza Vaccination belongs to the Recombinant protein vaccine class. See all Recombinant protein vaccine drugs at /class/recombinant-protein-vaccine.

What development phase is FluBlok Influenza Vaccination in?

FluBlok Influenza Vaccination is in Phase 3.

What are the side effects of FluBlok Influenza Vaccination?

Common side effects of FluBlok Influenza Vaccination include Injection site soreness, Headache, Muscle aches, Fatigue, Low-grade fever.

What does FluBlok Influenza Vaccination target?

FluBlok Influenza Vaccination targets Influenza hemagglutinin (HA) and is a Recombinant protein vaccine.

Related